Cover Image
市場調查報告書

EpiCast Report:痛風的流行病學預測

EpiCast Report: Gout - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 300492
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:痛風的流行病學預測 EpiCast Report: Gout - Epidemiology Forecast to 2023
出版日期: 2014年04月24日 內容資訊: 英文 55 Pages
簡介

痛風是發炎性關節炎的一種,是由於關節內部的尿酸結晶化所引發的疾病。此外也與高尿酸血症有關。全球主要6個國家的痛風發病人數,預測將由2013年的1,374,065人,增加到2023年的1,649,065人(年平均增加率為2.00%)。此外接受診斷的患病者人數推計將由2013年的17,625,944人,增加到2023年的17,625,944人(年平均成長率為2.82%)。

本報告提供全球主要6個國家(美國·法國·德國·義大利·西班牙·英國)的痛風發病情形和今後預測相關分析,提供疾病的特徵(風險要素和主要的併發症等等)全球各國的趨勢,目前患病者的發病情形,今後10年的發病·患病數量預測值等調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和併發症
  • 全世界的趨勢
    • 美國
    • 歐洲主要5個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 痛風的流行病學預測(今後11年份)
    • 接受診斷的發病人數
    • 接受診斷的患病人數
  • 議論
    • 流行病學的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER058

Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid. Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years.

GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%.

This forecast is supported by age- and sex-specific data obtained from country-specific estimates from peer reviewed journal articles, in which the study populations were representative of the general population in the respective markets. GlobalData epidemiologists used historical diagnosed incidence and diagnosed prevalence data which were available for Italy and the UK, along with linear regression methods to forecast the age- and sex-specific diagnosed incidence and diagnosed prevalence for Italy and the UK through 2023. The forecast provides the age- and sex-specific diagnosed incident cases and diagnosed prevalent cases of gout in each of the 6MM, with clinically relevant segmentations, which facilitate an in depth understanding of the emerging temporal trends, and informs strategies to improve the management of the disease. Additionally, GlobalData epidemiologists used the same methodology across the 6MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of gout across these markets.

Scope

  • The Gout EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at =85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.
  • The gout epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global gout market.
  • Quantify patient populations in the global gout market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gout therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Gout (2013-2023)
    • 3.5.1. Diagnosed Incidence
    • 3.5.2. Diagnosed Prevalence
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Gout
  • Table 2: Summary of Reported Incidence and Prevalence of Gout in the 6MM*
  • Table 3: American College of Rheumatology Criteria for the Clinical Diagnosis of Gout
  • Table 4: Sources of Gout Incidence Data in 6MM
  • Table 5: Sources of Gout Prevalence Data in 6MM
  • Table 6: Sources of Gout Flare and Tophaceous Gout Data in 6MM
  • Table 7: 6MM, Sources Not Used in the Epidemiological Analysis of Gout
  • Table 8: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 9: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 10: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N (Row %), 2013
  • Table 11: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 13: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Incidence of Gout (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N, 2013
  • Figure 7: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 8: 6MM, Age-Standardized Diagnosed Prevalence (%) of Gout, Ages ≥20 Years, by Sex, 2013
  • Figure 9: 6MM, Number of Gout Flares in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
  • Figure 10: 6MM, Tophaceous Gout Cases in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
Back to Top